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ellular, But Not Direct, Adenoviral
elivery of Vascular Endothelial Growth Factor
esults in Improved Left Ventricular Function and
eovascularization in Dilated Ischemic Cardiomyopathy
rman Askari, MD,* Samuel Unzek, MD,† Corey K. Goldman, MD, PHD,†
tephen G. Ellis, MD, FACC,* James D. Thomas, MD, FACC,* Paul E. DiCorleto, PHD,†
ric J. Topol, MD, FACC,* Marc S. Penn, MD, PHD, FACC*†
leveland, Ohio
OBJECTIVES We sought to compare the effects on angiogenesis and left ventricular (LV) function of
adenoviral vascular endothelial growth factor-165 (AdVEGF-165) gene delivery by direct
injection of AdVEGF-165 to the transplantation of skeletal myoblasts (SKMB) transfected
with AdVEGF-165 in a rat model of ischemic cardiomyopathy.
BACKGROUND Angiogenesis offers the potential for treating ischemic cardiomyopathy. However, the optimal
method of delivering angiogenic factors for neovascularization remains undetermined. With
the increased clinical interest in cell therapy for the treatment of LV dysfunction, SKMB
transplantation may serve as a means of gene transfer.
METHODS Two months after left anterior descending coronary artery ligation, rats received either
injection of an adenoviral construct encoding VEGF-165, or 1 million SKMB transfected
with AdLuciferase (AdLuc) or AdVEGF-165. Cardiac function was assessed echocardio-
graphically, and neovascularization was assessed histologically four weeks after therapy.
RESULTS Neovascularization was significantly increased by both AdVEGF delivery strategies (100 
7% and 185  33% increase in vascular density compared with SKMB alone, respectively).
However, cell-based delivery, but not direct injection of AdVEGF-165, resulted in increased
cardiac function (73.5  12.6% and 1.5  8.8% increase in shortening fraction compared
with saline control; AdLuc-transfected SKMB: 29.4  15.0%). The improved function was
not due to increased engraftment of VEGF expressing SKMB. Rather, improved function
correlated with less apoptosis in the border zone in those animals that received AdVEGF-165
expressing SKMB.
CONCLUSION Our data demonstrate that cell-based delivery of VEGF leads to an improved treatment effect
over direct adenoviral injection, and suggest that already developed adenoviral vectors that
encode secreted factors could potentially offer greater efficacy in combination with SKMB
transplantation. (J Am Coll Cardiol 2004;43:1908–14) © 2004 by the American College of
Cardiology Foundationp
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pherapeutic angiogenesis for the treatment of ischemic
eart disease has demonstrated efficacy in several animal
odels and human pilot trials in patients not suitable for
oronary revascularization. Angiogenic factors tested in
uman trials include fibroblast growth factor (FGF)-1, -2,
nd -4 and several isoforms of vascular endothelial growth
actor (VEGF) (1). The optimal delivery method to induce
eovascularization has yet to be determined.
Clinical strategies for delivery of angiogenic factors have
ncluded delivery of protein through intravenous (2) or
ntracoronary injection (2,3), intracoronary injection of
denovirus (4) or direct intramyocardial injection of
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Manuscript received August 26, 2003; revised manuscript received November 7,
m003, accepted December 23, 2003.rotein-coated beads (5), naked deoxyribonucleic acid (6),
r adenoviral-based angiogenic gene products (7). Intra-
oronary delivery strategies of VEGF protein are limited by
ystemic toxicities including hypotension that develop in
esponse to the high doses required to induce neovascular-
zation (8,9). Naked DNA requires direct myocardial injec-
ion due to rapid degradation by circulating nucleases.
We have recently demonstrated the potential efficacy of cell
ransplantation as a means for reestablishing stem cell homing
or the purpose of myocardial regeneration months after
yocardial infarction (MI) (10). Similarly, autologous skeletal
yoblast (SKMB) cell transplantation has shown some prom-
se for improving left ventricular (LV) function when delivered
ithin a few weeks of acute MI in multiple animal models
11–14), and is now being studied in clinical populations as an
djunct to coronary artery bypass grafting (15). The effects of
denoviral-mediated gene transfer to SKMB prior cell trans-
lantation in the setting of an ischemic cardiomyopathy
onths after MI has not been studied.
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May 19, 2004:1908–14 Cell Therapy for Gene TransferIn this study we directly compare the efficacy of two
elivery strategies of adenoviral vascular endothelial growth
actor-165 (AdVEGF-165) in a model of ischemic cardio-
yopathy. Because untoward biological effects of adenoviral
herapy are dose-dependent, we chose to compare equal
oses of adenovirus in each of two arms: direct injection of
dVEGF-165 versus injection of SKMB transfected with
dVEGF-165. Our data demonstrate that efficacy of cur-
ent adenoviral constructs encoding angiogenic factors can
e significantly enhanced by combining gene transfer with
ell transplantation due to a significant decrease in the
dverse effects of adenovirus with this strategy.
ETHODS
n our studies, ischemic cardiomyopathy was induced by
nterior wall MI in 60 150- to 175-g male Lewis rats
Harlan Labs, Indianapolis, Indiana) via ligation of the left
nterior descending (LAD) artery. Ischemic cardiomyopa-
hy developed for two months before randomization to
reatment strategy. There were three treatment groups in
ur study and two control groups. The control groups were
njection of saline or intramyocardial injection of 107 pfu of
denoviral Luciferase (AdLuc) in five divided doses. Two
roups were transplanted with 1 million SKMB that were
ransfected with 107 pfu of either AdVEGF-165 or AdLuc.
fourth group received five intramyocardial injections of
dVEGF-165 totaling 107 pfu.
AD ligation. The animal research committee approved
ll animal protocols. Animals were housed in the Associa-
ion for Assessment and Accreditation of Laboratory Ani-
al Care animal facility of the Cleveland Clinic Founda-
ion. Animals were anesthetized with sodium pentobarbital,
0 mg/kg, intubated, and ventilated with room air at 80
reaths/min using a pressure cycled rodent ventilator (Kent
cientific Corp., RSP1002, Torrington, Connecticut). An-
erior wall MI was induced by direct ligation of the LAD
ith the aid of a surgical microscope (Leica M500, Heer-
rugg, Switzerland).
wo-dimensional echocardiography. Two-dimensional
chocardiography was performed five to seven days and
ight weeks after LAD ligation using a 15-MHz linear array
ransducer interfaced with a Sequoia C256 (Siemens Med-
cal Solutions, Malvern, Pennsylvania). Two-dimensional
nd M-Mode echocardiography were also performed four
eeks after SKMB transplantation. Rats were lightly se-
Abbreviations and Acronyms
AdLuc  adenoviral Luciferase
AdVEGF-165  adenoviral vascular endothelial growth
factor-165
LAD  left anterior descending coronary artery
LV  left ventricle/ventricular
MI  myocardial infarction
SKMB  skeletal myoblastsated with ketamine (50 mg/kg) for each echocardiogram. 2eft ventricular dimensions and wall thickness were assessed
sing digitally recorded short-axis two-dimensional clips
nd M-Mode images from the mid-LV just below the
apillary muscles. Measurements were made offline using
roSolve (Problem Solving Concepts, Indianapolis, Indi-
na) by two blinded observers to treatment groups (16).
ach measurement in each animal was made six times, from
hree randomly chosen M-Mode clips out of five recorded.
hortening fraction (shortening fraction [%]  (LVEDD 
VESD)/LVEDD·100, where LVEDD  LV end-diastolic
imension and LVESD  LV end-systolic dimension) was
alculated from M-Mode recordings.
ell preparation and cell and viral delivery. Skeletal
yoblasts were harvested from the hind limbs of several
ewis rats (Harlan Labs), plated in 175 ml culture flask, and
rown in Dulbecco’s modified Eagle’s medium (DMEM)
ncluding 10% fetal bovine serum, 300 mg/l endothelial cell
rowth supplement, and the antibiotics penicillin, strepto-
ycin, and ofloxacin. Cells were passed once 75% conflu-
nce was achieved to avoid differentiation.
On the day before cell transplantation, purified myoblasts
ere transfected with 1  107 pfu/ml of replication defi-
ient, E1-, E3-deleted adenovirus-expressing VEGF-165
r adenovirus-expressing luciferase (control), both under the
ontrol of a cytomegalovirus promoter. Eight weeks after
AD ligation, myoblasts were harvested with trypsin,
ashed extensively in PBS to remove any free viral particles,
nd reconstituted immediately before transplantation. Ani-
als were then anesthetized, ventilated, and subjected to a
ateral thoracotomy for direct visualization of the infarct
one. Approximately 1  106 cells were injected per animal
n five locations in the peri-infarct zone. The volume of each
njection was 40 to 50 l using the same spatial distribution
or cell injections in all animals: two injections each along
he infarct border zones of the anterior-septal and posterior-
ateral walls and one injection near the apex of the infarct
one. Similarly, direct injection of AdVEGF-165 or AdLuc
nto the peri-infarct was accomplished through five injec-
ions of 0.2  107 pfu each. No injections were made into
he infarct zone. Volume of each injection was 100 l. In all
xperiments, two injections were made along the left and
wo along the right border of the peri-infarct zone; the fifth
njection was in the peri-infarct zone at the LV apex.
denoviral construct. The adenoviral construct encoding
EGF-165 and luciferase was a generous gift from Gen
ec Inc. (Gaithersburg, Maryland). Briefly, 293 cells were
btained from American Type Culture Collection (ATCC
RL. 1573, Manassas, Virginia) and were maintained in
MEM supplemented with 10% calf serum. The E1-,
3-deleted adenovirus-vector-encoding AdVEGF-165 or
uciferase was generated by linearizing the shuttle vector
lasmid at a unique restriction site adjacent to the left-end-
nverted-terminal repeat and co-transfected into 293 cells
ith ClaI-digested H5dl324 DNA (17). After two sequen-
ial plaque purifications, vector stocks were propagated on
93 cells and purified through three sequential bandings on
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Cell Therapy for Gene Transfer May 19, 2004:1908–14esium chloride gradients. The purified virus was dialyzed
gainst a buffer containing 10 mM Tris, pH 7.8, 150 mM
aCl, 10 mM MgCl2, and 3% sucrose and stored at80°C
ntil use. The transgene expression is under the control of
he cytomegalovirus immediate early promoter.
istologic analysis. Rats were euthanized, their hearts
arvested for analysis four weeks after cell transplantation
ollowing perfusion fixation with HistoChoice (Amresco
nc., Solon, Ohio), and sectioned into three equal divisions
erpendicular to the LV long axis. The mid-ventricular
ection was paraffin-embedded, and several sections 6-m
hick were obtained just below the papillary muscle for
nalysis. Sections were stained with hemotoxylin and eosin
or histologic analysis. To assist with blood vessel identifi-
ation, sections were stained using an antibody to von
illebrand Factor (DAKO, Carpinteria, California) and an
orseradish peroxidase-labeled goat anti-mouse secondary
ntibody. These sections were counterstained with hema-
oxylin. Blood vessels were counted throughout the infarct
one from four sections from each animal by a trained
bserver blinded to the identity of each animal.
Infarct size was quantified from hematoxylin-and-eosin-
tained cross-sections from the mid-LV. Infarct size was
uantified by % LV area containing infarcted tissue; how-
ver, because these hearts were 12 weeks after MI and the
nterior wall had significantly thinned, the % area contain-
ng infarcted tissue did not adequately reflect the size of the
I induced by LAD ligation. Therefore, we also quantified
he percent of the LV cavity circumference that had in-
arcted tissue.
easurement of apoptosis by TUNEL assay. Apoptotic
ells were identified by direct staining of the condensed
uclei or fragmented DNA with TUNEL-based staining
In Situ Cell Death Detection Kit, AP. Roche, Basel,
witzerland) (18). Tissues were deparaffinized, and the
UNEL reaction mixture comprised by a label and an
nzyme solution was placed over the sections and incubated
n a humidified chamber at 37°C for 1 h. The slides were
insed and subsequently incubated with the Converter-AP
anti-fluorescein antibody Fab fragments from sheep, con-
ugated with alkaline phosphatase) for 30 min also in a
umidifying chamber. After treatment with lavamisole to
nhibit endogenous alkaline phosphase activity, a substrate
olution (alkaline phosphatase substrate kit, Vector Labo-
able 1. LV Wall Thickness, Cavity Dimensions, and Shortenin
Treatment
Wall Thickness (mm)
Anterior Posterior E
aline (n  7) 0.85  0.07 2.30  0.1
dLUC (n  4) 0.87  0.10 2.78  0.25
dVEGF (n  4) 0.93  0.09 2.67  0.18
KMB (n  7) 0.84  0.07 2.33  0.14
KMB  AdVEGF (n  6) 0.85  0.15 2.47  0.27
reatment was begun eight weeks after LAD ligation. *p  0.05 compared with sal
LAD  left anterior descending coronary artery; LV  left ventricular; SKMB atories, Burlingame, California) was added for 45 min, and Aissues were counterstained with hematoxylin. In parallel, a
ositive control was done using DNAase I before labeling
rocedures to verify specificity of staining. Observers
linded to treatment quantified the number of TUNEL-
ositive cells per field from sections obtained from the
id-ventricle. Cardiac myocytes were identified by their
istinct histologic appearance. Five high power fields (120
uclei/field) were assessed from each animal. The apoptotic
ndex is the number of TUNEL-positive cells per 100 cells.
tatistical analysis. Data are presented as mean  SD.
omparisons between groups were by Student t test, or by
nalysis of variance.
ESULTS
ffect of SKMB transplantation on LV function. The
oal of our study was to determine if SKMB expressing
EGF-165 led to significant neovascularization of the
nfarct zone and improved LV function. Therefore, our
nitial experiments focused on the effects of syngeneic
KMB transplantation on vascular density and LV func-
ion. Transplantation of SKMB transfected with AdLuc
nto the peri-infarct zone eight weeks after LAD ligation
id not result in neovascularization of the infarct zone (data
ot shown). Skeletal myoblast transplantation did, however,
roduce a 30% increase in LV function as measured by
hortening fraction at the level of the papillary muscle
Table 1).
eovascularization in response to cell-based and direct
denoviral VEGF delivery. We compared the angiogenic
esponse between direct injection of AdVEGF-165 to
ransplantation of SKMB transfected with AdVEGF-165
r AdLuc. We held constant the biologic dose of control
AdLuc) or AdVEGF-165 adenovirus used in each exper-
mental arm to 1  107 pfu. To verify that we had similarly
ized infarcts in each of the treatment groups, infarct size
as quantified from hematoxylyn-and-eosin-stained cross-
ections from the mid-ventricle 12 weeks after acute MI
four weeks after treatment). The infarct size, whether
easured as % of LV cavity circumference bordering the
nfarct zone (Table 1) or % of LV area of infarcted tissue
data not shown), was not significantly different between
hose animals that received direct injection of saline, Ad-
EGF, AdLuc, transplantation of SKMB transfected with
ction Four Weeks After the Designated Treatment
V Dimensions (mm)
Shortening
Fraction (%)
Infarct Size
(% LV Cavity
Circumference)ystolic End-Diastolic
0.6 10.3  0.6 6.8  2.1 46.2  5.1
1.0 11.6  1.3 6.2  2.0 44.9  6.3
1.0 11.2  1.1 6.9  1.2 43.5  8.1
 1.1 9.9  0.8 8.9  2.7* 45.1  3.3
 1.2 10.1  1.2 11.8  2.1*† 48.7  6.9
oup; †p  0.05 compared with AdVEGF group. Data represent mean  SD.
etal myocyte.g Fra
L
nd-S
9.6 
10.8 
10.4 
9.0
8.8
ine grdLuc, or AdVEGF.
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May 19, 2004:1908–14 Cell Therapy for Gene TransferThe vascular density within the infarct zone was quanti-
ed by counting von Willebrand factor-stained vessels in
issue sections obtained just below the level of the papillary
uscles. We found a significant increase in vascular density
n those animals that received either injection of AdVEGF-
65 or cell transplantation with VEGF-165 expressing
KMB (Fig. 1) compared with hearts that were trans-
lanted with AdLuc-transfected SKMB. There was no
ross or histologic evidence of hemangioma formation with
ny treatment strategy. A significantly greater increase in
ascular density was seen in those animals treated with
ransplantation of SKMB expressing VEGF compared with
irect AdVEGF injection (Fig. 1).
The representative photomicrographs in Figure 2 show
hat the infarct zone following AdLuc-transfected SKMB
ransplantation is relatively avascular (Fig. 2A). The neo-
ascularization after VEGF-165 therapy by either modality
esults in the development of increased vascular density as
haracterized by an increase in the number of capillaries and
mall arterioles (Figs. 2B and 2C).
ell-based delivery of VEGF results in improved LV
unction. To determine if either direct viral injection or
ell-based expression of VEGF-165 leads to improved LV
unction, echocardiography was performed 12 weeks after
I (four weeks after treatment). The LAD ligation model
sed for these studies resulted in a significant decrease in
hortening fraction. Improved LV function was seen in the
earts that underwent transplantation with SKMB express-
ng VEGF-165 compared with hearts that received direct
njection of AdVEGF-165 (Table 1, Fig. 3). Furthermore,
he improvement in LV function seen with transplantation
f VEGF-165 expressing SKMB was significantly greater
igure 1. Direct adenoviral injection or transplantation of cells expressing
ascular endothelial growth factor (VEGF)-165 induces neovasculariza-
ion. Eight weeks after myocardial infarction induced by left anterior
escending coronary artery ligation, the peri-infarct zone was injected with
ither 1  107 pfu of adenoviral VEGF-165 (AdVEGF-165) (n  4) or 1
illion skeletal myoblast (SKMB) transfected with AdLuciferase (n  7)
r AdVEGF-165 (n 6) in five equally divided injections. The vasculature
as identified by von Willebrand factor immunohistochemistry, and
ascular density was quantified throughout the infarct zone. Data represent
ean SD. *p 0.01 compared with SKMB transplantation alone. &p
.05 compared with AdVEGF injection.han that seen with transplantation of AdLuc-transfected sKMB. Despite a significant increase in vascular density
ith direct injection of AdVEGF-165, no improvement in
V function compared with saline injection alone was seen.
irect injection of 107 pfu of AdLuc did not result in a
tatistically significant decrease in LV function (Table 1).
ffect of cell-based delivery of VEGF-165 on SKMB
ngraftment. To determine if the improved LV function
ith transplantation of VEGF-165 expressing SKMB was
ue to greater engraftment and survival of the SKMB into
he infarct border zone, total protein extracts from pulver-
zed LVs were assessed for SKMB content by Western blot
nalysis using an antibody (MY-32, 200 kD) specific for
keletal myocyte heavy chain myosin (Fig. 4A). Five days
fter sham operation or transplantation with 1  106
KMB transfected with AdLuc or AdVEGF-165, MY-32
as seen only in animals that received SKMB transplanta-
ion (Fig. 4A). Using this approach, we demonstrated that
ransfecting cells with AdVEGF-165 or AdLuc before
ransplantation did not result in any difference in skeletal
yosin heavy chain content in the transplanted heart (Fig.
B), suggesting similar levels of SKMB engraftment and
igure 2. Vascular endothelial growth factor (VEGF)-165 induces neo-
ascularization in the infarct zone. Representative sections of the infarct
one four weeks after injection into the peri-infarct zone of either 1 million
keletal myoblasts (SKMB) transfected with AdLuciferase (A, D), 1 107
fu adenoviral VEGF-165 (AdVEGF-165) (B, E), or 1 million SKMB
ransfected with AdVEGF-165 (C, F) in five equally divided injections.
A, B, C) H & E staining and (D, E, F) immunohistochemistry for von
illebrand factor.urvival between treatment groups. These data are consis-
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Cell Therapy for Gene Transfer May 19, 2004:1908–14ent with hypothesis that the augmented LV function seen
ith transplantation of SKMB-expressing VEGF was not
ue to increased SKMB engraftment.
ell-based AdVEGF delivery attenuates the inflamma-
ory response and reduces apoptosis in the infarct border
one. To better understand plausible mechanisms leading
o augmented LV function in animals receiving SKMB-
ased VEGF, we assessed hearts histologically for the
nflammatory response to AdLuc or AdVEGF delivery and
mmunohistochemically for apoptosis. Four weeks after
reatment, the peri-infarct zone in animals injected with
denovirus consistently revealed a robust inflammatory in-
ltrate (data not shown) that was not present in any of the
nimals transplanted with VEGF-165 expressing SKMB.
n addition, a paucity of apoptotic cells were visualized in
nimals that received either SKMB alone or VEGF-
xpressing SKMB (Figs. 5A, 5C, and 5D); however, direct
njection of AdVEGF induced a significantly greater num-
er of apoptotic cells within the peri-infarct border zone at
our weeks after treatment (Fig. 5B). The direct injection of
dLuc resulted in similar levels of apoptosis as seen in
esponse to AdVEGF (Fig. 5D). Importantly, some of the
UNEL-positive cells within the infarct border zone were
ardiac myocytes (Figs. 5B and 5D).
ISCUSSION
herapeutic gene transfer for the induction of neovascular-
zation may be beneficial for patients who are not candidates
or coronary revascularization for the treatment of their
yocardial ischemia (2–5,7), or as an adjunct to coronary
evascularization. Local delivery of angiogenic factors min-
mizes untoward systemic effects of angiogenesis, such as
igure 3. Transplantation of vascular endothelial growth factor (VEGF)-
65 expressing skeletal myoblasts (SKMB) significantly increases LV
unction. Eight weeks after myocardial infarction, the peri-infarct zone was
njected with either saline (n  7), 1  107 pfu of adenoviral VEGF-165
AdVEGF-165) (n  4), or 1 million SKMB transfected with AdLucif-
rase (n  7) or AdVEGF-165 (n  6) in five equally divided injections.
eft ventricular function was quantified four weeks later by echocardio-
ram. Left ventricular function is presented as shortening fraction (%)
elative to saline control. Data represent mean  SEM. *p  0.03
ompared with saline control. &p  0.05 compared with SKMB.umor growth and retinopathy, and permits precise target- dng of desired neovascularization. Furthermore, transient
xpression of angiogenic factors appears to be sufficient to
nduce neovascularization and minimize systemic effects and
emangioma formation (19). Multiple strategies have been
tudied for delivering angiogenic growth factors including
irect injection of purified angiogenic proteins, plasmid, or
iral constructs that encode for these proteins.
Autologous SKMB transplantation is a potential treat-
ent modality for the treatment of ischemic cardiomyopa-
hy. Several preclinical studies have demonstrated aug-
ented LV systolic and diastolic function with SKMB
ransplantation (11,12). In addition, preliminary clinical
tudies have demonstrated feasibility and safety of SKMB
ransplantation, prompting active clinical trials (15,20). The
otential for utilizing skeletal myoblasts as vehicles of gene
igure 4. Adenoviral vascular endothelial growth factor (AdVEGF-165)
ransfection does not alter skeletal myoblast (SKMB) engraftment. (A)
epresentative lanes from Western blot analyses of 50 g of protein extract
rom whole hearts five days after sham operation (n 3), or transplantation
ith 1  106 SKMB transfected with either AdLuciferase (n  3) or
dVEGF-165 (n 4) 18 h before transplantation using antibodies specific
o either skeletal myocyte myosin heavy chain (MY-32) or the light chain
f cardiac myosin. (B) Quantification of MY-32 bands from Western blot
nalysis in arbitrary units. Data represent mean  SD. p  NS SKMB vs.
KMB  AdVEGF-165.elivery has been suggested in recent animal studies (21–
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May 19, 2004:1908–14 Cell Therapy for Gene Transfer3); however, it has never been directly compared to the
reatment effects of direct viral injection.
We tested the hypothesis that viral transfection of SKMB
efore transplantation with an adenoviral construct encod-
ng for VEGF-165 would be more efficacious at inducing
eovascularization and improving LV function than direct
dVEGF delivery or SKMB transplantation alone, in a
odel of ischemic cardiomyopathy. Transplantation of
KMB after adenoviral-mediated gene transfer has the
dvantage over the transplantation of SKMB following
etroviral, lentiviral, adeno-associated viral, or stable trans-
ection because gene expression after adenoviral-mediated
ransfection is transient. In the case of VEGF gene transfer,
hronic VEGF expression could theoretically lead to hem-
ngioma formation or retinopathy. Consistent with prior
tudies, transplantation of 1 million SKMB did not induce
ignificant neovascularization but resulted in improved LV
unction.
The same amount of AdVEGF-165 resulted in signifi-
ant increases in neovascularization by both delivery strat-
gies studied (Fig. 1). However, transplantation of VEGF-
65 expressing SKMB resulted in an 70% increase in LV
unction, and no improvement in LV function was observed
igure 5. Adenoviral vascular endothelial growth factor-165 (AdVEGF-16
order zone. Representative TUNEL-stained (red) nuclei in sections from t
SKMB), (B) 1  107 pfu AdVEGF-165, or (C) 1 million SKMB transfec
umber of TUNEL-positive cells (white bars) and TUNEL-positive card
600 nuclei) from the infarct border zone per animal. Data represent m
ransfected SKMB for both Luc and VEGF-165. No significant differencith direct injection of AdVEGF-165 (Fig. 3). The in-rease in LV function was not due to greater SKMB survival
ithin days after transplantation (Fig. 4).
Plausible mechanisms for the synergistic improvement in
V function observed with transplantation of VEGF-
xpressing SKMB and a lack of improvement in LV
unction observed in AdVEGF-treated animals despite
ncreased neovascularization may relate to the induced
nflammatory response to therapy and to apoptosis.
denoviral-mediated gene transfer to the myocardium has
een shown to cause robust myocardial inflammation and
ardiac myocytes apoptosis (24). We found a significantly
reater inflammatory response in the myocardial infarct
order zone four weeks after direct AdVEGF injection
ompared with an absence of inflammation in the myocar-
ium injected with AdVEGF-transfected SKMB. Further-
ore, TUNEL staining revealed a substantial proportion of
poptotic cells, including apoptotic cardiac myocytes, within
he infarct border zone of animals that received direct
dVEGF compared with SKMB-based VEGF delivery.
imilar differences in apoptotic index of cardiac myocytes as
e observed between SKMB and direct AdVEGF injection
ave been shown to result in significant differences in LV
unction (18).
ection results in increased TUNEL-positive cardiac myocytes in the infarct
ri-infarct zone four weeks after injection of (A) 1 million skeletal myoblasts
ith 1  107 pfu AdVEGF-165 each in five equally divided injections. (D)
yocytes (black bars) per 100 nuclei as quantified in five high power fields
 SD. n  4 animals per group. p  0.01 direct viral injection versus
re observed between VEGF-165 and Luc within each delivery strategy.5) inj
he pe
ted w
iac m
ean
es weBased on these findings, it is plausible that both delivery
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ardium, but that the deleterious inflammatory effects in-
uced by the direct injection of AdVEGF-165 negates these
eneficial effects. Thus, while increasing the dose of
dVEGF-165 or re-administering AdVEGF-165 into the
nfarct border zone at a later time may result in similar levels
f angiogenesis as transplantation of AdVEGF-165-
ransfected SKMB, it is unlikely that this would result in
mproved LV function given the potential for further
xacerbating the inflammatory response.
The current study confirms and extends existing data that
utologous differentiated cell transplantation can augment
V function in a model of ischemic cardiomyopathy at a
ime remote from the MI. We further demonstrate a simple
trategy for potentially improving the clinical efficacy of
lready developed adenoviral constructs that encode secreted
olecules, and we suggest a testable strategy for future
rials.
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